Back to top
more

MyoKardia, Inc. (MYOK)

(Delayed Data from NSDQ)

$49.32 USD

49.32
555,613

+1.92 (4.05%)

Updated May 3, 2019 04:00 PM ET

After-Market: $49.29 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should You Invest in the SPDR SP Pharmaceuticals ETF (XPH)?

by Zacks Equity Research

Sector ETF report for XPH

Bristol-Myers (BMY) Q3 Earnings Beat, '20 EPS View Raised

by Zacks Equity Research

Bristol-Myers (BMY) beats on earnings and sales in the third quarter on strength of Revlimid and Eliquis.

Qorvo, Nikola, BMY, MyoKardia and Geron as Zacks Bull and Bear of the Day

by Zacks Equity Research

Qorvo, Nikola, BMY, MyoKardia and Geron as Zacks Bull and Bear of the Day

Is a Beat in the Cards for Bristol-Myers' (BMY) Q3 Earnings?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports third-quarter 2020 results.

Sweta Killa headshot

M&A ETF (MNA) Hits New 52-Week High

by Sweta Killa

This M&A ETF hits a new 52-week high. Are more gains in store for this ETF?

Bristol Myers (BMY) Gains on Positive Opdivo Data in NSCLC

by Zacks Equity Research

Bristol Myers' (BMY) shares gain as the phase III study evaluating Opdivo plus chemotherapy meets primary endpoint for the indication of NSCLC.

The Zacks Analyst Blog Highlights: Gilead, JNJ, Sanofi, BMY and MyoKardia

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Gilead, JNJ, Sanofi, BMY and MyoKardia

Biotech Stock Roundup: ALXN to Raise Guidance, BMY to Buy MYOK & Other Updates

by Zacks Equity Research

The biotech sector remains in focus with regulatory, acquisition and other pipeline updates.

Kinjel Shah headshot

Pharma M&As Pick Up as Bristol-Myers Offers to Buy MyoKardia

by Kinjel Shah

After a relatively dull first half of 2020, M&A activity in the drug and biotech sector seems to be picking up in the second half of 2020.

Sweta Killa headshot

Healthcare ETFs Pop on Bristol Myers-MyoKardia Deal

by Sweta Killa

These funds could be the best ways for investors to tap the opportunity arising from the Bristol Myers-MyoKardia deal and will likely see smooth trading in the months to come.

Company News for Oct 6, 2020

by Zacks Equity Research

Companies in the news are: TSLA, MYOK, EIDX, GAN

Bristol Myers to Buy MyoKardia to Aid Cardiovascular Franchise

by Zacks Equity Research

Bristol Myers (BMY) offers $13.1 billion to acquire MyoKardia for diversifying its cardiovascular product portfolio. The transaction is expected to close in the fourth quarter of 2020.

Company News for May 12, 2020

by Zacks Equity Research

Companies In The News Are:

Is the Options Market Predicting a Spike in MyoKardia (MYOK) Stock?

by Zacks Equity Research

Investors need to pay close attention to MyoKardia (MYOK) stock based on the movements in the options market lately.

Sweta Killa headshot

First-Mover Pandemic Disease Fight ETF On The Way

by Sweta Killa

Pacer Financial has filed for Pacer BioThreat ETF to enjoy the first-mover advantage that provide investors an option to capitalize on the new opportunities triggered by coronavirus.

Are Options Traders Betting on a Big Move in MyoKardia (MYOK) Stock?

by Zacks Equity Research

Investors need to pay close attention to MyoKardia (MYOK) stock based on the movements in the options market lately.

Implied Volatility Surging for MyoKardia (MYOK) Stock Options

by Zacks Equity Research

Investors need to pay close attention to MyoKardia (MYOK) stock based on the movements in the options market lately.

MyoKardia Begins Dosing in Phase I Study on Heart Candidate

by Zacks Equity Research

MyoKardia (MYOK) doses the first patient in phase I study on MYK-224, which is being evaluated for treating patients with hypertrophic cardiomyopathy, a common heart disease.

MyoKardia (MYOK) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

MyoKardia (MYOK) delivered earnings and revenue surprises of -5.06% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

MyoKardia (MYOK) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

MyoKardia (MYOK) delivered earnings and revenue surprises of -43.08% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

MyoKardia (MYOK) in Focus: Stock Moves 7.3% Higher

by Zacks Equity Research

MyoKardia (MYOK) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Zacks.com featured highlights include: Athene, MyoKardia and Euronav

by Zacks Equity Research

Zacks.com featured highlights include: Athene, MyoKardia and Euronav

Tirthankar Chakraborty headshot

3 Earnings Acceleration Stocks You Really Need to Look At

by Tirthankar Chakraborty

Studies have shown that a majority of successful stocks had seen acceleration in earnings before an uptick in the stock price.

MyoKardia (MYOK) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

MyoKardia (MYOK) delivered earnings and revenue surprises of 22.00% and 21.45%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

MyoKardia (MYOK) Q3 Earnings Preview: What's Shaping Up?

by Zacks Equity Research

MyoKardia (MYOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.